Sunscreen suit and preparation method

Abstract

The present invention provides a sunscreen kit, which comprises: (i) formulation A, comprising: 10-20 weight percent of oil, 0.5-30 weight percent of sunscreen, 3-25 weight percent of hydrogenated polydimethylsiloxane, 5-35 weight percent of vinyl polydimethylsiloxane, 1-10 weight percent of emulsifier, optionally 1-10 weight percent of silica, and a cosmetics acceptable carrier; and (ii) formulation B, comprising: 1-10 weight percent of a colloidal platinum composition, 1-10 weight percent of light scattering particles, and a cosmetics acceptable carrier; wherein the colloidal platinum composition comprises: 0.1-10 weight percent of a metal platinum salt, 1-20 weight percent of a fatty acid having 8-30 carbon atoms, 0.01-5 weight percent of an organosilane having 10-60 carbon atoms, and a cosmetics acceptable solvent, wherein the solvent is propylene glycol. The present invention also relates to the application of the kit in the cosmetics field.

Description

Technical Field

[0001] The present invention relates to the field of cosmetics, and in particular to a waterproof, sweat-resistant and highly effective sun-proof suit, and a preparation method and application thereof. Background Art

[0002] In daily life, the majority of UV rays come from sunlight. While moderate UV exposure is beneficial to human health, excessive UV exposure can easily cause melanin deposition, leading to darkening of the skin. It can also trigger irreversible tissue damage in the dermis, leading to aging symptoms such as sagging skin, and, in more severe cases, skin cancer and other diseases. With increasing health awareness, engaging in outdoor activities has become a popular lifestyle. This increase in outdoor activities has also led to a corresponding increase in demand for sun protection products such as sun-protective clothing, umbrellas, and sunscreen. Sunscreen, with its many advantages such as effectiveness, portability, convenience, and ease of use, has become a must-have in daily life. Research based on consumer usage behavior shows that sweat secreted during outdoor activities can damage the sunscreen coating on the skin, directly reducing its effectiveness. This is particularly noticeable at the beach or in other water-related, high-humidity, and high-temperature environments. Therefore, it is recommended that sunscreen be reapplied approximately 1-2 hours after use. This research finding significantly impacts consumer convenience and affordability, becoming a major pain point. Therefore, developing waterproof and sweat-resistant sunscreen products has become the best way to solve this pain point.

[0003] At present, there are two main technical approaches to improve waterproof and sweat resistance:

[0004] First, the omission of film-forming agents significantly increases the amount of sunscreen used. This type of formulation often feels greasy, heavy, and spreads poorly on the skin, resulting in a poor user experience and relatively high formulation costs. Furthermore, the use of large amounts of sunscreen increases potential safety risks.

[0005] Second: Use a pre-polymerized film-forming agent, such as polyurethane, polyacrylic acid, and polyacrylamide. The larger the molecular weight of the film-forming agent, the stronger its film-forming ability. However, if the film-forming ability is too strong, it can leave the skin feeling thick and sticky, and can also cause discomfort such as airtightness later on. If the molecular weight is too low, the film will be less uniform, thicker, and stronger, resulting in a sunscreen that lacks adequate water and sweat resistance.

[0006] Therefore, a new technology needs to be developed in this field, in which organosiloxanes (hydrogenated polydimethylsiloxane and vinyl polydimethylsiloxane in formulation A) are cross-linked on-site on the skin (through the action of colloidal platinum in formulation B) to form a transparent invisible film with waterproof and sweat-resistant properties, which can address the shortcomings of the above two technical paths, thereby directly solving consumers' pain points and improving the performance of sunscreen products. Summary of the Invention

[0007] In one aspect, the present invention provides a sun protection kit comprising:

[0008] (i) Dosage form A, comprising:

[0009] 10-20% by weight of fat,

[0010] 0.5-30% by weight of sunscreen,

[0011] 3-25 wt% of hydrogenated polydimethylsiloxane having a viscosity of 10 to 130 cSt at 25°C,

[0012] 5-35% by weight of vinyl polydimethylsiloxane having a viscosity of 55,000 to 95,000 cSt at 25°C,

[0013] 1-10% by weight of an emulsifier,

[0014] Optionally, 1-10 wt% silica, and

[0015] A cosmetically acceptable carrier; and

[0016] (ii) Dosage Form B, comprising:

[0017] 1-10% by weight of a colloidal platinum composition,

[0018] 1-10% by weight of light scattering particles,

[0019] A carrier acceptable in the cosmetic field;

[0020] Wherein, the colloidal platinum composition comprises:

[0021] 0.1-10% by weight of a metal platinum salt,

[0022] 1-20% by weight of fatty acids having 8-30 carbon atoms,

[0023] 0.01-5% by weight of an organosilane having 10-60 carbon atoms,

[0024] A cosmetically acceptable solvent, the solvent being propylene glycol.

[0025] In a preferred embodiment, the emulsifier in the formulation A is dimethicone PEG-10 / 15 crosspolymer.

[0026] In a preferred embodiment, the silica in the dosage form A is selected from the group consisting of silica, silica silylate, silica dimethyl silylate, polydimethylsiloxane silica silylate, hydrated silica, or a combination thereof.

[0027] In a preferred embodiment, the colloidal platinum composition in the dosage form B further comprises polyvinyl pyrrolidone having a K value of 28-34.

[0028] In a preferred embodiment, the metal platinum salt in the colloidal platinum composition in the dosage form B is selected from: chloroplatinic acid, potassium hexachloroplatinate, sodium chloroplatinate, platinum acetylacetonate, or a combination thereof.

[0029] In a preferred embodiment, the fatty acid in the colloidal platinum composition in the dosage form B is selected from palmitic acid, oleic acid, stearic acid, lauric acid, behenic acid, or a combination thereof.

[0030] In a preferred embodiment, the organosilane in the colloidal platinum composition in Formulation B is selected from: trimethoxyoctylsilane, triethoxyoctylsilane, or a combination thereof.

[0031] In a preferred embodiment, the light scattering particles in the dosage form B are nylon-12 and isopropyl titanium triisostearate.

[0032] In a preferred embodiment, the formulation B further comprises the following ingredients: silicone oil, silicone elastomer, emulsifier, polyol or a combination thereof.

[0033] In a preferred embodiment, the set is in the form of a dual-dose package or two separate packages.

[0034] In another aspect, the present invention provides a method for using the kit, comprising applying formulation A evenly to the skin surface until absorbed, and then applying formulation B to the skin surface. DETAILED DESCRIPTION

[0035] The present invention provides a waterproof, sweat-resistant, and highly effective sunscreen suit, comprising formulation A and formulation B. Formulation A is the product applied in the first step, which comprises a sunscreen, a film-forming monomer vinyl polydimethylsiloxane, hydrogenated polydimethylsiloxane, and silica. Formulation B is the product applied in the second step, which comprises colloidal platinum and light-scattering particles. After the tester uses the waterproof, sweat-resistant, and highly effective sunscreen suit prepared according to the method of the present invention (for example, 15 minutes later), a uniform, light sunscreen coating is formed on the skin surface. The SPF test result is 82.6, and after the waterproof test, the SPF value is 76.0. This proves that it has a good waterproof and sweat-proof effect.

[0036] In order to provide a more concise description, some quantitative expressions given herein are not modified by the term "about". It should be understood that, regardless of whether the term "about" is explicitly used, each quantity given herein is intended to refer to the actual given value and also to refer to the approximate value of these given values ​​that can be reasonably estimated by a person of ordinary skill in the art, including the approximate value of these given values ​​caused by experimental and / or measurement conditions.

[0037] To provide a more concise description, some quantitative expressions herein are described as a range of about X amount to about Y amount. It should be understood that when a range is described, the range is not limited to the upper and lower limits described, but should include the entire range of about X amount to about Y amount or any amount therebetween.

[0038] I.Dosage Form A

[0039] Formulation A in the high-efficiency sunscreen kit described in the present application is the product to be applied in the first step, and the product comprises a sunscreen, vinyl dimethicone, hydrogenated dimethicone, an emulsifier, and optionally silica.

[0040] sunscreen

[0041] The sunscreens included in Formulation A of the set of the present invention are collectively referred to as inorganic sunscreens and organic sunscreens. The inorganic sunscreens are collectively referred to as titanium dioxide, zinc oxide, surface-treated titanium dioxide, carbon dioxide coatings, surface-modified zinc oxide, and zinc oxide coatings. The organic sunscreens are also collectively referred to as avobenzone, butyl methoxydibenzoylmethane, homosalate, octocrylene, ethylhexyl methoxycinnamate, ethylhexyl salicylate, benzophenone-3, phenylbenzimidazole sulfonic acid, ethylhexyl triazone, diethylamino hydroxybenzoyl hexyl benzoate, bis-ethylhexyloxyphenol methoxyphenyl triazine, methylene bis-benzotriazolyl tetramethylbutylphenol, polysilicone-15, 4-methylbenzylidene camphor, benzophenone-4, and benzophenone-5, or a combination thereof.

[0042] In some embodiments of the present invention, the content of sunscreen in Formulation A of the kit described herein is 0.5-30% by weight. In some embodiments of the present invention, Formulation A of the kit comprises 0.5%-20% by weight of sunscreen. In some embodiments of the present invention, Formulation A of the kit comprises 1%-20% by weight of sunscreen.

[0043] Siloxane

[0044] Formulation A in the kit of the present invention contains vinyl dimethicone, whose INCI name is VINYLDIMETHICONE. The viscosity specification of the vinyl dimethicone used in the present invention is required to be 55,000 to 95,000 cSt at 25°C. In a preferred embodiment, the viscosity of the vinyl dimethicone used in the present invention is 55,000 to 80,000 cSt. In a preferred embodiment, the viscosity of the vinyl dimethicone used in the present invention is 60,000 to 80,000 cSt.

[0045] In some embodiments of the present invention, the content of vinyl dimethicone in the dosage form A of the kit described herein is 5-50% by weight. In some embodiments of the present invention, the dosage form A of the kit comprises 5-35% by weight of vinyl dimethicone. In some embodiments of the present invention, the dosage form A of the kit comprises 5-20% by weight of vinyl dimethicone.

[0046] Formulation A of the kit of the present invention contains hydrogenated dimethicone, whose INCI name is HYDROGENDIMETHICONE. The viscosity of the hydrogenated dimethicone used in the present invention is required to be 10 to 130 cSt at 25°C. In a preferred embodiment, the viscosity of the hydrogenated dimethicone used in the present invention is 15 to 100 cSt.

[0047] In some embodiments of the present invention, the content of hydrogenated polydimethylsiloxane in the formulation A of the kit described herein is 1-35% by weight. In some embodiments of the present invention, the formulation A of the kit comprises 3-25% by weight of hydrogenated polydimethylsiloxane. In some embodiments of the present invention, the formulation A of the kit comprises 5-20% by weight of hydrogenated polydimethylsiloxane.

[0048] Silicones (e.g., hydrogenated polydimethylsiloxane and / or vinyl polydimethylsiloxane in Formulation A) can crosslink on-site on the skin (e.g., through the action of colloidal platinum in Formulation B) to form a transparent invisible film with a highly effective sun protection effect.

[0049] emulsifiers

[0050] The dosage form A of the kit of the present invention comprises an emulsifier. In a specific embodiment, the emulsifier used in dosage form A is polydimethylsiloxane PEG-10 / 15 crosspolymer.

[0051] In some embodiments of the present invention, the content of dimethicone PEG-10 / 15 crosspolymer in the dosage form A of the kit described herein is 1-10% by weight. In some embodiments of the present invention, the dosage form A of the kit comprises 1-5% by weight of dimethicone PEG-10 / 15 crosspolymer. In some embodiments of the present invention, the dosage form A of the kit comprises 2-5% by weight of dimethicone PEG-10 / 15 crosspolymer.

[0052] silica

[0053] The dosage form A of the kit of the present invention optionally contains silica. The silica used in the dosage form A is a general term including silica, silica silylate, silica dimethyl silylate, silica polydimethylsiloxane silylate, hydrated silica and other combinations.

[0054] In some embodiments of the present invention, the content of silica in the dosage form A of the kit described herein is 1-10% by weight. In some embodiments of the present invention, the dosage form A of the kit contains 5-10% by weight of silica.

[0055] Other ingredients in dosage form A

[0056] The dosage form A of the set of the present invention may further comprise other ingredients. For example, the dosage form A of the set of the present application may comprise oil, thickener, preservative, pH adjuster, etc.

[0057] In some specific embodiments, the oil contained in the formulation A of the set is selected from the group consisting of isononyl isononanoate, polydimethylsiloxane, or a combination thereof. In some preferred embodiments, the amount of oil in the formulation A is 10-20% by weight.

[0058] In some specific embodiments, the formulation A of the kit comprises an acrylic acid ester / C10-30 alkyl acrylate crosspolymer. In some preferred embodiments, the amount of acrylic acid ester / C10-30 alkyl acrylate crosspolymer in formulation A is 0.1-5% by weight. In some preferred embodiments, the amount of acrylic acid ester / C10-30 alkyl acrylate crosspolymer in formulation A is 0.5-1.5% by weight.

[0059] In some specific embodiments, the dosage form A of the kit contains phenoxyethanol. In some preferred embodiments, the amount of phenoxyethanol in the dosage form A is 0.1-1% by weight.

[0060] In some specific embodiments, the dosage form A of the kit comprises tromethamine. In some preferred embodiments, the amount of tromethamine in the dosage form A is 0.1-1% by weight.

[0061] Preparation method of dosage form A

[0062] The present invention also provides a method for preparing dosage form A.

[0063] The formulation A of the present invention can be prepared according to the following raw materials in weight percentage: 10-20% oil, 0.001-30% sunscreen, 3-25% hydrogenated polydimethylsiloxane, 5-35% vinyl polydimethylsiloxane, 1-10% silica, 2-5% emulsifier, 0.5-1.5% thickener, 0.1-1% preservative and 40-60% deionized water.

[0064] Specifically, the preparation method of dosage form A of the present invention comprises the following steps:

[0065] (a) mixing a sunscreen, vinyl dimethicone, hydrogenated dimethicone, silica, oil, and emulsifier to form an oil phase;

[0066] (b) taking a portion of deionized water, adding a thickener, dissolving it until fully swollen, and adding other ingredients such as a preservative to form the aqueous phase;

[0067] (c) Slowly add the aqueous phase to the oil phase to obtain formulation A.

[0068] In one specific embodiment, the preparation process of Formulation A includes the following steps: uniformly mixing a sunscreen, vinyl polydimethylsiloxane, hydrogenated polydimethylsiloxane, silica, oil, and emulsifier at a temperature range of 25-60°C to form the oil phase. Add a thickener to a portion of the deionized water and dissolve until fully swollen to form the aqueous phase. Evenly mix the remaining deionized water and preservative and add the aqueous phase. Slowly add the aqueous phase to the oil phase at a temperature range of 25-60°C, stirring and homogenizing for 5-15 minutes; continue stirring, slowly cool to room temperature, and form a milky white cream, which is then sealed and stored away from light.

[0069] II. Dosage Form B

[0070] Formulation B in the high-efficiency sunscreen kit described in the present application is a product applied in the second step, comprising a colloidal platinum composition and light-scattering particles.

[0071] Colloidal platinum composition

[0072] This application first discovered that the selection of solvents and additives is crucial during the preparation of colloidal platinum compositions. The present invention innovatively discovered that by using specific solvents (e.g., propylene glycol) and additives (e.g., fatty acids and organosilanes), the resulting colloidal platinum compositions have particle sizes within the range of 0.5-5 nm and maintain long-term stability.

[0073] In some embodiments of the present invention, the content of the colloidal platinum composition in the dosage form B of the kit described herein is 0.01-10% by weight. In some embodiments of the present invention, the dosage form B of the kit comprises 0.01-5% by weight of the colloidal platinum composition. In some embodiments of the present invention, the dosage form B of the kit comprises 1-5% by weight of the colloidal platinum composition.

[0074] Metal platinum salts of colloidal platinum compositions

[0075] The invention provides a colloidal platinum composition, which contains colloidal platinum, a raw material specially used for top-grade cosmetics, as an active ingredient.

[0076] In an embodiment of the present invention, the metal platinum salt is selected from: chloroplatinic acid (cas: 16941-12-1, chemical formula: H2PtCl6·6H2O), potassium hexachloroplatinate (cas: 16921-30-5, chemical formula: K2PtCl6), sodium chloroplatinate (cas: 19583-77-8, chemical formula: Na2PtCl6·6H2O), acetylacetonate (cas: 15170-57-7, chemical formula: C 10 H 14 In a preferred embodiment, the metal platinum salt is chloroplatinic acid.

[0077] In some embodiments of the present invention, the colloidal platinum composition described herein comprises a metal platinum salt in an amount of 0.1-10% by weight. In some embodiments of the present invention, the colloidal platinum composition comprises a metal platinum salt in an amount of 0.1-8% by weight. In some embodiments of the present invention, the composition comprises a metal platinum salt in an amount of 0.1-5% by weight. In some embodiments of the present invention, the composition comprises a metal platinum salt in an amount of 0.1-4% by weight.

[0078] Solvent for colloidal platinum composition

[0079] Colloidal platinum is a liquid containing negatively charged platinum nanoparticles suspended in it. Ethylene glycol is commonly used as a solvent for preparing colloidal platinum compositions. For example, the use of ethylene glycol is reported in the literature (Nano Today, 2009, 4, 143-164). However, ethylene glycol is toxic and can damage internal organs such as the kidneys, liver, stomach, and intestines. Furthermore, ethylene glycol is listed as a restricted organic solvent in the Appendix to Part II of the 2010 edition of the Chinese Pharmacopoeia.

[0080] Propylene glycol, whose INCI name is PROPYLENE GLYCOL. The present applicant unexpectedly discovered that using propylene glycol as a solvent for preparing colloidal platinum compositions not only retains the advantages of propylene glycol, such as being non-toxic, non-corrosive, biodegradable, and safer, but also maintains the stability of the prepared colloidal platinum compositions. Therefore, the present applicant discovered for the first time that propylene glycol is the optimal solvent for preparing colloidal platinum compositions.

[0081] In some embodiments of the present invention, the amount of solvent in the colloidal platinum composition described herein is equal to or greater than 50% by weight. In some embodiments of the present invention, the colloidal platinum composition comprises 40-95% by weight of solvent. In some embodiments of the present invention, the composition comprises 50-90% by weight of solvent. In some embodiments of the present invention, the composition comprises 60-90% by weight of solvent. In some embodiments of the present invention, the composition comprises 70-90% by weight of solvent.

[0082] Additives to colloidal platinum compositions

[0083] The present invention unexpectedly discovered that fatty acids and organosilanes play a key role in the preparation of colloidal platinum compositions.

[0084] The addition of fatty acids plays a key role in controlling the particle size of colloidal platinum.

[0085] Fatty acids are a class of compounds composed of three elements: carbon, hydrogen, and oxygen. They are the main components of neutral fats, phospholipids, and glycolipids. Fatty acid metabolism Fatty acids can be divided into the following categories according to the length of their carbon chains: short-chain fatty acids, which have less than 6 carbon atoms on their carbon chains, also known as volatile fatty acids; medium-chain fatty acids, which refer to fatty acids with 6-12 carbon atoms on their carbon chains, the main components of which are caprylic acid (C8) and capric acid (C10); and long-chain fatty acids, which have more than 12 carbon atoms on their carbon chains. In a preferred embodiment of the present invention, the additives used are medium-chain or long-chain fatty acids. In a preferred embodiment, fatty acids with 8-30 carbon atoms are used. In a more preferred embodiment, fatty acids with 10-26 carbon atoms are used. In a more preferred embodiment, fatty acids with 12-22 carbon atoms are used. In a specific embodiment, fatty acids with 12, 14, 16, 18, 20, or 22 carbon atoms are used.

[0086] Fatty acids can be divided into three categories based on whether their carbon-hydrogen chains are saturated or unsaturated: saturated fatty acids, which have no unsaturated bonds between carbon and hydrogen; monounsaturated fatty acids, which have one unsaturated bond between carbon and hydrogen; and polyunsaturated fatty acids, which have two or more unsaturated bonds between carbon and hydrogen. Saturated, monounsaturated, or polyunsaturated fatty acids can be used in the colloidal platinum compositions of the present invention.

[0087] In a preferred embodiment, the fatty acid is selected from the group consisting of palmitic acid, oleic acid, stearic acid, lauric acid, behenic acid, or a combination thereof. In a most preferred embodiment, the fatty acid is oleic acid.

[0088] In some embodiments of the present invention, the amount of fatty acid in the colloidal platinum composition described herein is 1-20% by weight. In some embodiments of the present invention, the colloidal platinum composition comprises 1-15% by weight of fatty acid. In some embodiments of the present invention, the composition comprises 2-15% by weight of fatty acid. In some embodiments of the present invention, the composition comprises 3-10% by weight of fatty acid. In some embodiments of the present invention, the composition comprises 5-10% by weight of fatty acid.

[0089] The addition of organosilane helps to maintain the long-term stability of colloidal platinum activity.

[0090] In some embodiments of the present invention, organosilanes having 10-60 carbon atoms are used. In preferred embodiments, organosilanes having 10-30 carbon atoms are used. In more preferred embodiments, organosilanes having 10-26 carbon atoms are used. In still more preferred embodiments, organosilanes having 10-20 carbon atoms are used. In specific embodiments, organosilanes having 11, 14, 17, or 20 carbon atoms are used.

[0091] In a preferred embodiment, the organosilane is selected from: trimethoxyoctylsilane, triethoxyoctylsilane or a combination thereof. In a more preferred embodiment, the organosilane is trimethoxyoctylsilane.

[0092] In some embodiments of the present invention, the amount of organosilane in the colloidal platinum composition described herein is 0.01-5% by weight. In some embodiments of the present invention, the colloidal platinum composition comprises 0.01-1% by weight of the organosilane. In some embodiments of the present invention, the colloidal platinum composition comprises 0.1-2% by weight of the organosilane. In some embodiments of the present invention, the composition comprises 0.1-1% by weight of the organosilane. In some embodiments of the present invention, the composition comprises 0.1-0.5% by weight of the organosilane.

[0093] Other ingredients in colloidal platinum compositions

[0094] The colloidal platinum composition of the present invention may further comprise other ingredients.

[0095] For example, in one embodiment of the present invention, the composition further comprises polyvinylpyrrolidone. Polyvinylpyrrolidone, abbreviated as PVP, is a non-ionic polymer compound. PVP is divided into four grades according to its average molecular weight, which is usually expressed as a K value. Different K values ​​represent the corresponding range of PVP average molecular weight. The K value is actually a characteristic value related to the relative viscosity of the PVP aqueous solution. Viscosity is a physical quantity related to the molecular weight of the polymer. Therefore, the K value can be used to characterize the average molecular weight of PVP. Generally, the larger the K value, the greater the viscosity and the stronger the adhesion.

[0096] In a specific embodiment, the K value of the polyvinyl pyrrolidone contained in the composition is required to be in the range of 28-34.

[0097] In some embodiments of the present invention, the amount of polyvinyl pyrrolidone in the colloidal platinum composition described herein is 1-30% by weight. In some embodiments of the present invention, the colloidal platinum composition comprises 2-30% by weight of polyvinyl pyrrolidone. In some embodiments of the present invention, the composition comprises 2-20% by weight of polyvinyl pyrrolidone. In some embodiments of the present invention, the composition comprises 2-15% by weight of polyvinyl pyrrolidone. In some embodiments of the present invention, the composition comprises 1-10% by weight of polyvinyl pyrrolidone.

[0098] Preparation method of colloidal platinum composition

[0099] The present invention also provides a method for preparing the colloidal platinum composition.

[0100] The colloidal platinum composition of the present invention can be prepared according to the following raw materials in weight percentage: 0.1%-4% of metal platinum salt, 2%-30% of polyvinyl pyrrolidone, 60%-90% of propylene glycol, 5%-15% of fatty acid, and 0.01%-1% of organosilane.

[0101] Specifically, the method for preparing the colloidal platinum composition of the present invention comprises the following steps:

[0102] (a) mixing a metal platinum salt, polyvinyl pyrrolidone, and propylene glycol to obtain a first mixture;

[0103] (b) adding a fatty acid to the first mixture to obtain a second mixture;

[0104] (c) adding organosilane to the second mixture to finally obtain the colloidal platinum composition of the present invention.

[0105] In one embodiment, the method for preparing a colloidal platinum composition of the present invention comprises the following steps: uniformly mixing a metal platinum salt, polyvinyl pyrrolidone, and propylene glycol at room temperature in the aforementioned amounts; rapidly stirring, heating to 110-200°C, and maintaining the temperature for 2-8 hours; adding a fatty acid, raising the temperature to 120-250°C, and continuing stirring for 30-90 minutes; then cooling the mixture to 60-80°C, adding an organosilane, and maintaining the temperature with stirring for 30-90 minutes; finally, cooling the mixture to room temperature; discharging the mixture, and the colloidal platinum is completed. Store in a cool, dark place.

[0106] The colloidal platinum composition prepared by the present invention has an average particle size of 0.5-5 nm. In a preferred embodiment, the colloidal platinum composition of the present invention has an average particle size of 1-5 nm. In a preferred embodiment, the colloidal platinum composition of the present invention has an average particle size of 1-3 nm.

[0107] In the colloidal platinum composition prepared by the present invention, more than 75% of the particles have a particle size within the range of 1.75 ± 0.5 nm. In a preferred embodiment, more than 80% of the particles in the composition have a particle size within the range of 1.75 ± 0.5 nm. In a more preferred embodiment, more than 90% of the particles in the composition have a particle size within the range of 1.75 ± 0.5 nm.

[0108] Light scattering particles

[0109] Formulation B in the high-efficiency sunscreen kit described herein contains light-scattering particles. In some embodiments of the present invention, the light-scattering particles include: nylon-12, isopropyl titanium triisostearate, silicone resin, or a combination thereof.

[0110] In some embodiments of the present invention, the light scattering particles in the dosage form B of the set described herein are present in an amount of 1-10% by weight. In some embodiments of the present invention, the dosage form A of the set comprises 2-8% by weight of light scattering particles. In some embodiments of the present invention, the dosage form A of the set comprises 2-5% by weight of light scattering particles.

[0111] Other ingredients in dosage form B

[0112] The formulation B of the set of the present invention may further comprise other ingredients. For example, the formulation A of the set of the present application may comprise silicone oil, silicone elastomer, emulsifier, polyol, preservative, and the like.

[0113] In some embodiments of the present invention, the formulation B of the kit comprises cyclopentasiloxane. In some specific embodiments, the formulation B comprises 10-20% by weight of cyclopentasiloxane.

[0114] In some embodiments of the present invention, the formulation B of the kit comprises dimethicone crosspolymer. In some specific embodiments, the formulation B comprises 1-15% by weight of dimethicone crosspolymer.

[0115] In some embodiments of the present invention, the polyol contained in the formulation B of the kit is selected from glycerol, butylene glycol, hexylene glycol or a combination thereof. In some specific embodiments, the formulation B contains 20-40% by weight of the polyol.

[0116] In some embodiments of the present invention, the emulsifier contained in the formulation B of the kit is selected from the group consisting of: cetyl PEG / PPG-10 / 1 dimethicone, dimethicone PEG-10 / 15 crosspolymer, or a combination thereof. In some specific embodiments, formulation B contains 2-5% by weight of the emulsifier.

[0117] Preparation method of dosage form B

[0118] The present invention also provides a preparation method of dosage form B.

[0119] The formulation B of the present invention can be prepared according to the following raw materials in weight percentage: silicone oil 10-20%, silicone elastomer 1-15%, emulsifier 2-5%, light scattering particles 2-8%, colloidal platinum composition 0.01-2%, polyol 20-40%, preservative 0.1-1%, and deionized water 25-45%.

[0120] Specifically, the preparation method of dosage form B of the present invention comprises the following steps:

[0121] (a) mixing silicone oil, silicone elastomer, emulsifier, and light scattering particles to form an oil phase;

[0122] (b) taking a portion of deionized water, adding a polyol and a preservative, and dissolving them fully to form the aqueous phase;

[0123] (c) preparing a colloidal platinum composition as an additive phase;

[0124] (d) The aqueous phase was slowly added to the oil phase, and then the additive phase was added to obtain formulation B.

[0125] In one specific embodiment, the preparation process of Formulation B comprises the following steps: uniformly mixing silicone oil, silicone elastomer, emulsifier, and light-scattering particles at a temperature range of 25-60°C to form the oil phase. A polyol and preservative are added to a portion of deionized water and dissolved thoroughly to form the aqueous phase. Colloidal platinum is added separately to form the additive phase. The aqueous phase is slowly added to the oil phase at a temperature range of 25-60°C, stirring and homogenizing for 5-15 minutes; the additive phase is then added, stirring and homogenizing continued for 5-15 minutes, and an opaque gel is formed, which is then sealed and stored away from light.

[0126] III. Application of the Set

[0127] The present invention also relates to the use of the highly effective sunscreen kit in the cosmetics field. Specifically, the application method includes first applying Formulation A to the desired area of ​​skin. After complete absorption, Formulation B is then applied to the desired area, and then waiting, for example, 3 to 10 minutes. The kit of the present invention achieves highly effective sun protection. For example, in one embodiment, the SPF test result was 82.6, while after a water resistance test, the SPF value was 76.0. This demonstrates that the kit of the present invention exhibits excellent water and sweat resistance.

[0128] Long-lasting sweat resistance and water resistance ensure excellent sun protection. The sunscreen technology of the present invention forms an invisible protective film on the skin surface, protecting the skin from UV damage in places with significant sunlight, such as the seaside or outdoor swimming pools.

[0129] The present invention will be further described below with reference to specific examples. It should be noted that the examples are intended only to further illustrate the present invention and are not to be construed as limiting the scope of the present invention. Those skilled in the art may make non-essential improvements and adjustments based on the above-described disclosure of the present invention. The test methods in the following examples, for which specific conditions are not specified, are generally based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise indicated, all percentages and parts are by weight.

[0130] Example 1: Preparation of colloidal platinum composition

[0131] At room temperature, mix 1% chloroplatinic acid, 5% polyvinylpyrrolidone, and 85.5% propylene glycol. Stir rapidly, heat to 110°C, and maintain for 2 hours. Add 8% oleic acid, raise the temperature to 120°C, and continue stirring for 30 minutes. Then, cool to 60°C, add 0.5% trimethoxyoctylsilane, and maintain stirring at this temperature for 30 minutes. Finally, cool to room temperature. Discard the product, and colloidal platinum is ready. Store in a cool, dark place.

[0132] Comparative Example 1: Preparation of colloidal platinum composition

[0133] At room temperature, mix 1% chloroplatinic acid, 5% polyvinylpyrrolidone, and 86% propylene glycol. Stir rapidly, heat to 110°C, and maintain for 2 hours. Add 8% oleic acid, raise the temperature to 120°C, and continue stirring for 30 minutes. Finally, cool to room temperature. Discard the mixture, and colloidal platinum is ready. Store in a cool, dark place.

[0134] Comparative Example 2: Preparation of Colloidal Platinum Composition

[0135] At room temperature, mix 1% chloroplatinic acid, 5% polyvinylpyrrolidone, and 93.5% propylene glycol. Stir rapidly, heat to 110°C, and maintain for 2 hours. Then, cool to 60°C, add 0.5% trimethoxyoctylsilane, and maintain stirring at this temperature for 30 minutes. Finally, cool to room temperature. Discard the product, and colloidal platinum is ready. Store in a cool, dark place.

[0136] Comparative Example 3: Preparation of Colloidal Platinum Composition

[0137] At room temperature, mix 1% chloroplatinic acid, 5% polyvinylpyrrolidone, and 94% propylene glycol. Stir rapidly, heat to 110°C, and maintain for 2 hours. Finally, cool to room temperature. Discard the solution, and colloidal platinum is ready. Store in a cool, dark place.

[0138] Test Example 1: Stability Study of Colloidal Platinum Composition

[0139] The stability evaluation method is as follows: The colloidal platinum compositions prepared in Example 1 and Comparative Examples 1-3 were placed in a stable, high-temperature (40°C) thermostat for 30 days. The samples were observed for signs of solid precipitation, surface blackening, and delamination. If the sample remained normal and unchanged before and after a certain time within the 30-day period, it was considered "OK." The presence of particles indicated "precipitation," localized blackening indicated "blackening," and the presence of two layers of liquid indicated "delamination." The results are shown in the table below.

[0140] Table 1: Stability study of different additives

[0141]

[0142] As shown in Table 1, by comparing the results of Example 1 and Comparative Example 1, it is found that if no organosilane is added as a stabilizer to the colloidal platinum composition, the colloidal platinum composition will turn black after 30 days. By comparing the results of Example 1 and Comparative Example 2, it is found that if no fatty acid is added during the preparation of the colloidal platinum composition, solid precipitation and agglomeration will occur after 7 days. By comparing the results of Example 1 and Comparative Example 3, it is shown that the addition of fatty acid and organosilane during the preparation process of the colloidal platinum composition plays an important role in the stability of the colloidal platinum composition.

[0143] Example 2: Preparation of colloidal platinum composition

[0144] At room temperature, mix 0.5% potassium hexachloroplatinate, 3% polyvinylpyrrolidone, and 90.2% propylene glycol. Stir rapidly, heat to 110°C, and maintain for 2 hours. Add 6% stearic acid, raise the temperature to 120°C, and continue stirring for 30 minutes. Then, cool to 60°C, add 0.3% triethoxyoctylsilane, and maintain stirring at this temperature for 30 minutes. Finally, cool to room temperature. Discard the product, and colloidal platinum is ready. Store in a cool, dark place.

[0145] Example 3: Preparation of colloidal platinum composition

[0146] At room temperature, mix 2.5% sodium chloroplatinate, 15% polyvinylpyrrolidone, and 67.5% propylene glycol. Stir rapidly, heat to 110°C, and maintain for 2 hours. Add 14% lauric acid, raise the temperature to 120°C, and continue stirring for 30 minutes. Then, cool to 60°C, add 1% trimethoxyoctylsilane, and maintain stirring at this temperature for 30 minutes. Finally, cool to room temperature. Discard the product, and colloidal platinum is ready. Store in a cool, dark place.

[0147] Example 4: Preparation of colloidal platinum composition

[0148] At room temperature, mix 3% platinum acetylacetonate, 20% polyvinylpyrrolidone, and 66.1% propylene glycol. Stir rapidly, heat to 110°C, and maintain for 2 hours. Add 10% behenic acid, raise the temperature to 120°C, and continue stirring for 30 minutes. Then, cool to 60°C, add 0.9% triethoxyoctylsilane, and maintain stirring at this temperature for 30 minutes. Finally, cool to room temperature. Discard the product, and colloidal platinum is ready. Store in a cool, dark place.

[0149] Example 5: Preparation of colloidal platinum composition

[0150] At room temperature, mix 0.5% chloroplatinic acid, 0.2% platinum acetylacetonate, 10% polyvinylpyrrolidone, and 76.5% propylene glycol. Stir rapidly, heat to 110°C, and maintain for 2 hours. Add 2% palmitic acid and 10% oleic acid, raise the temperature to 120°C, and continue stirring for 30 minutes. Then, cool to 60°C, add 0.8% trimethoxyoctylsilane, and maintain stirring at this temperature for 30 minutes. Finally, cool to room temperature. Discard the product, and colloidal platinum is ready. Store in a cool, dark place.

[0151] Example 6: Preparation of colloidal platinum composition

[0152] At room temperature, mix 0.1% sodium chloroplatinate, 0.1% platinum acetylacetonate, 3% polyvinylpyrrolidone, and 92.7% propylene glycol. Stir rapidly, heat to 110°C, and maintain for 2 hours. Add 1% stearic acid and 3% oleic acid, raise the temperature to 120°C, and continue stirring for 30 minutes. Then, cool to 60°C, add 0.1% trimethoxyoctylsilane, and maintain stirring at this temperature for 30 minutes. Finally, cool to room temperature. Discard the mixture, and colloidal platinum is ready. Store in a cool, dark place.

[0153] Example 7: Preparation of colloidal platinum composition

[0154] At room temperature, mix 2% chloroplatinic acid, 2% sodium chloroplatinate, 30% polyvinylpyrrolidone, and 50% propylene glycol. Stir rapidly, heat to 110°C, and maintain for 2 hours. Add 15% oleic acid, raise the temperature to 120°C, and continue stirring for 30 minutes. Then, cool to 60°C, add 1% trimethoxyoctylsilane, and maintain stirring at this temperature for 30 minutes. Finally, cool to room temperature. Discard the product, and colloidal platinum is ready. Store in a cool, dark place.

[0155] Test Example 2: Stability Study of Colloidal Platinum Composition

[0156] The stability evaluation method is as follows: The colloidal platinum compositions prepared in Examples 2-7 were placed in a stable, high-temperature (40°C) thermostat for 30 days. The samples were observed for signs of solid precipitation, surface blackening, and delamination. If the samples remained normal and unchanged before and after a certain time within the 30-day period, they were considered "OK." The presence of particles indicated precipitation, localized blackening indicated darkening, and the presence of two layers of liquid indicated delamination. The results are shown in Table 2 below.

[0157] Table 2: Stability study of different raw materials

[0158]

[0159] As shown in Table 2, the results of Examples 2 to 5 indicate that the metal platinum salt selected for the colloidal platinum can be selected from chloroplatinic acid, potassium hexachloroplatinate, sodium chloroplatinate, and platinum acetylacetonate, all of which can achieve good results. The results of Examples 4, 6, and 7 indicate that trimethoxyoctylsilane and triethoxyoctylsilane can both produce colloidal platinum compositions with good stability. Comparison of all the above results indicates that, in the process of preparing colloidal platinum, fatty acids selected from palmitic acid, oleic acid, stearic acid, lauric acid, and behenic acid can all achieve satisfactory results.

[0160] The colloidal platinum compositions obtained in the above experiments not only exhibited excellent stability but also maintained a high level of activity. Because colloidal platinum can promote the cross-linking reaction of silicone, a cosmetic containing silicone and a sunscreen was used as the first formulation (Formulation A), while a cosmetic containing the colloidal platinum composition was used as the second formulation (Formulation B).

[0161] This study designed a dual-formulation product: Formulation A, which contains silicone and sunscreen, and Formulation B, which contains a colloidal platinum compound. Formulation A is pre-applied to a designated skin area, followed by Formulation B. The colloidal platinum compound promotes cross-linking of silicone on the skin surface, providing water-resistant, sweat-resistant, and sun-blocking properties.

[0162] The following are examples of specific applications of the colloidal platinum composition of the present invention in external skin preparations, as well as the formulations and preparation methods of these preparations. In the following tables, "-" indicates no additive.

[0163] Table 3: Formulation A (Product Examples 4 / 5 / 6, Application Example 1)

[0164]

[0165] Table 4: Formulation B (Product Examples 4-6, Application Example 1)

[0166]

[0167] Product Example 4:

[0168] Preparation of dosage form A

[0169] According to the above formula and dosage, 20% vinyl dimethicone (viscosity: 10,000 cSt), 10.00% hydrogenated dimethicone, 5.00% dimethicone, 3.00% isononyl isononanoate, 2.00% ethylhexyl salicylate, 5.00% ethylhexyl methoxycinnamate, 2.00% bis-ethylhexyloxyphenol methoxyphenyl triazine, 1.50% diethylamine hydroxybenzoyl hexyl benzoate, and 4% dimethicone PEG-10 / 15 crosspolymer were thoroughly mixed at a temperature range of 25°C to 60°C to form the oil phase. Acrylates / C10-30 Alkyl Acrylate Crosspolymer was added to 30% deionized water and dissolved and fully swollen to form the aqueous phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexylene glycol, and continue adding the aqueous phase. Slowly add the aqueous phase to the oil phase at a temperature between 25°C and 60°C, stirring and homogenizing for 5-15 minutes. Continue stirring and slowly cool to room temperature to form a milky white cream. Store sealed and away from light.

[0170] Preparation of dosage form B

[0171] At a temperature between 45°C and 60°C, uniformly mix 15% cyclopentasiloxane, 1% dimethicone crosspolymer, 4% cetyl PEG / PPG-10 / 1 dimethicone, 1% dimethicone PEG-10 / 15 crosspolymer, 4.5% nylon-12, and isopropyl titanium triisostearate to form the oil phase. Dissolve 52.9% deionized water, 5% glycerin, 15% butylene glycol, 0.3% phenoxyethanol, and 0.3% ethylene glycol to form the aqueous phase. Separately, add 1% of the colloidal platinum composition from Example 1 to form the additive phase. Slowly add the aqueous phase to the oil phase at a temperature between 25°C and 60°C, stirring and homogenizing for 5-15 minutes. Then, add the additive phase and continue stirring and homogenizing for 5-15 minutes to form an opaque gel. Seal and store in a dark place.

[0172] Product Example 5:

[0173] Preparation of dosage form A

[0174] According to the above formula and dosage, 20% vinyl dimethicone (viscosity: 180,000 cSt), 10% hydrogenated dimethicone, 5.00% dimethicone, 3.00% isononyl isononanoate, 2.00% ethylhexyl salicylate, 5.00% ethylhexyl methoxycinnamate, 2.00% bis-ethylhexyloxyphenol methoxyphenyl triazine, 1.50% diethylamine hydroxybenzoyl hexyl benzoate, and 4% dimethicone PEG-10 / 15 crosspolymer were thoroughly mixed at a temperature range of 25°C to 60°C to form the oil phase. Acrylates / C10-30 Alkyl Acrylate Crosspolymer was added to 30% deionized water and dissolved and fully swollen to form the aqueous phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexylene glycol, and continue adding the aqueous phase. Slowly add the aqueous phase to the oil phase at a temperature between 25°C and 60°C, stirring and homogenizing for 5-15 minutes. Continue stirring and slowly cool to room temperature to form a milky white cream. Store sealed and away from light.

[0175] Preparation of dosage form B

[0176] At a temperature between 45°C and 60°C, uniformly mix 15% cyclopentasiloxane, 1% dimethicone crosspolymer, 4% cetyl PEG / PPG-10 / 1 dimethicone, 1% dimethicone PEG-10 / 15 crosspolymer, 4.5% nylon-12, and isopropyl titanium triisostearate to form the oil phase. Dissolve 52.9% deionized water, 5% glycerin, 15% butylene glycol, 0.3% phenoxyethanol, and 0.3% ethylene glycol to form the aqueous phase. Separately, add 1% of the colloidal platinum composition from Example 1 to form the additive phase. Slowly add the aqueous phase to the oil phase at a temperature between 25°C and 60°C, stirring and homogenizing for 5-15 minutes. Then, add the additive phase and continue stirring and homogenizing for 5-15 minutes to form an opaque gel. Seal and store in a dark place.

[0177] Product Example 6:

[0178] Preparation of dosage form A

[0179] According to the above formula and dosage, 20% vinyl dimethicone (viscosity: 60,000 cSt), 10% hydrogenated dimethicone, 5.00% dimethicone, 3.00% isononyl isononanoate, 2.00% ethylhexyl salicylate, 5.00% ethylhexyl methoxycinnamate, 2.00% bis-ethylhexyloxyphenol methoxyphenyl triazine, 1.50% diethylamine hydroxybenzoyl hexyl benzoate, and 4% dimethicone PEG-10 / 15 crosspolymer were thoroughly mixed at a temperature range of 25°C to 60°C to form the oil phase. Acrylates / C10-30 Alkyl Acrylate Crosspolymer was added to 30% deionized water and dissolved and fully swollen to form the aqueous phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexylene glycol, and continue adding the aqueous phase. Slowly add the aqueous phase to the oil phase at a temperature between 25°C and 60°C, stirring and homogenizing for 5-15 minutes. Continue stirring and slowly cool to room temperature to form a milky white cream. Store sealed and away from light.

[0180] Preparation of dosage form B

[0181] At a temperature between 45°C and 60°C, uniformly mix 15% cyclopentasiloxane, 1% dimethicone crosspolymer, 4% cetyl PEG / PPG-10 / 1 dimethicone, 1% dimethicone PEG-10 / 15 crosspolymer, 4.5% nylon-12, and isopropyl titanium triisostearate to form the oil phase. Dissolve 52.9% deionized water, 5% glycerin, 15% butylene glycol, 0.3% phenoxyethanol, and 0.3% ethylene glycol to form the aqueous phase. Separately, add 1% of the colloidal platinum composition from Example 1 to form the additive phase. Slowly add the aqueous phase to the oil phase at a temperature between 25°C and 60°C, stirring and homogenizing for 5-15 minutes. Then, add the additive phase and continue stirring and homogenizing for 5-15 minutes to form an opaque gel. Seal and store in a dark place.

[0182] Application Example 1:

[0183] Preparation of dosage form A

[0184] According to the above formulation, 20% vinyl dimethicone (viscosity: 60,000 cSt), 10% hydrogenated dimethicone, 5.00% dimethicone, 3.00% isononyl isononanoate, 4% dimethicone PEG-10 / 15 crosspolymer, 8% silica, 2.00% ethylhexyl salicylate, 5.00% ethylhexyl methoxycinnamate, 2.00% bis-ethylhexyloxyphenol methoxyphenyl triazine, and 1.50% diethylamine hydroxybenzoyl hexyl benzoate were thoroughly mixed at a temperature range of 25°C to 60°C to form the oil phase. 0.5% acrylates / C10-30 alkyl acrylate crosspolymer was added to 25% deionized water and dissolved and fully swollen to form the aqueous phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexylene glycol, and continue adding the aqueous phase. Slowly add the aqueous phase to the oil phase at a temperature between 25°C and 60°C, stirring and homogenizing for 5-15 minutes. Continue stirring and slowly cool to room temperature to form a milky white cream. Store sealed and away from light.

[0185] Preparation of dosage form B

[0186] At a temperature between 45°C and 60°C, uniformly mix 15% cyclopentasiloxane, 1% dimethicone crosspolymer, 4% cetyl PEG / PPG-10 / 1 dimethicone, 1% dimethicone PEG-10 / 15 crosspolymer, 4.5% nylon-12, and isopropyl titanium triisostearate to form the oil phase. Dissolve 52.9% deionized water, 5% glycerin, 15% butylene glycol, 0.3% phenoxyethanol, and 0.3% ethylene glycol to form the aqueous phase. Separately, add 1% of the colloidal platinum composition from Example 1 to form the additive phase. Slowly add the aqueous phase to the oil phase at a temperature between 25°C and 60°C, stirring and homogenizing for 5-15 minutes. Then, add the additive phase and continue stirring and homogenizing for 5-15 minutes to form an opaque gel. Seal and store in a dark place.

[0187] Test Example 3: Sunscreen and Waterproof Performance Determination

[0188] (1) Determination of SPF value

[0189] Analytes: Samples prepared as Sample Nos. 1-4 (as shown in Table 5);

[0190] Reference Standard:

[0191] (1) Low SPF standard (P7), SPF value 4.4±0.4;

[0192] (2) high SPF standard product (P7), SPF value 16.1±2.4;

[0193] (3) High SPF standard product (P7), SPF value 15.7±2.0; select according to actual situation.

[0194] Subjects: 8 groups with 10 subjects in each group, 3 males and 7 females in each group, aged 20 to 59 years old, who met the voluntary inclusion criteria.

[0195] Light source: Daylight simulator xenon arc lamp, all performance tests meet the requirements of the specification;

[0196] Test method: The test is carried out in accordance with the specific requirements of the "Technical Specifications for Cosmetics" (2015 edition). The subject takes a prone position and their back is irradiated. The minimum erythema dose (MED value) of the subject's skin to ultraviolet irradiation is predicted 24 hours before the test. The ultraviolet irradiation dose is adjusted according to the predicted results and used to test the sample. On the day of the test, a normal area of ​​5*6cm2 is first selected on the subject's back. The sample to be tested or the standard reference substance is evenly applied to the above area at a sample dosage of (2.00±0.05)g / cm2. Then, an appropriate ultraviolet irradiation dose is selected and irradiated in three conditions: (1) the subject's skin is not smeared with the sample; (2) the standard reference sample is applied; (3) the sample number 1-4 of the present invention is applied; the results are observed for 24 hours, and the MED values ​​of the three conditions are recorded respectively.

[0197] SPF value calculation method: The SPF value of a sample or standard product protecting a single subject is expressed as follows: SPF value = MED value of protected skin / MED value of unprotected skin;

[0198] (2) Determination of waterproof performance

[0199] Tested objects: Sample numbers 1 to 4 after the above SPF test (as shown in Table 5)

[0200] Standard control samples: selected according to actual conditions, (1) low SPF standard (P7), SPF value 4.4±0.4; (2) high SPF standard (P7), SPF value 16.1±2.4; (3) high SPF standard (P7), SPF value 15.7±2.0;

[0201] Subjects: The same subjects as those in the above-mentioned sunscreen SPF test, where the SPF test was performed before bathing; for this waterproof performance test, the same subjects were bathed and the SPF value was tested.

[0202] Light source: Daylight simulator xenon arc lamp, all performance tests meet the requirements of the specification;

[0203] Test method: The test is conducted in accordance with the specific requirements of the "Technical Specifications for Cosmetics" (2015 edition). The subject is in a forward-leaning position and their back is irradiated. The minimum erythema dose (MED value) of the subject's skin to ultraviolet radiation is predicted 24 hours before the test. The ultraviolet radiation dose is adjusted according to the predicted results for the test sample. On the day of the test, a normal area of ​​5*6cm2 is first selected on the subject's back. Samples No. 1 to 4 (as shown in Table 5) or standard reference substances are evenly applied to the above area at a sample dosage of (2.00±0.05)g / cm2. The subject waits for 15 minutes, and the subject moves moderately in the water or the water rotates at a moderate level for 20 minutes. After exiting the water, rest for 20 minutes (do not wipe the test area with a towel). After entering the water, perform moderate activities for 20 minutes (do not wipe the test area with a towel). After finishing the activities in the water, wait for the skin to dry (do not wipe the test area with a towel). Then, select an appropriate ultraviolet irradiation dose and perform irradiation in three conditions: (1) no sample is applied to the subject's skin; (2) a standard control sample is applied; (3) sample numbers 1-4 of the present invention (as shown in Table 5) are applied. Observe the results for 24 hours and record the MED values ​​for the three conditions.

[0204] SPF value calculation method: The SPF value of a sample or standard product protecting a single subject is expressed as follows:

[0205] SPF value = MED value of protected skin / MED value of unprotected skin;

[0206] The calculation results of each group were taken as the average value of all subjects in the group. The results of each embodiment are shown in Table 5;

[0207] Table 5: SPF value before and after bathing

[0208]

[0209] As can be seen from Table 5, for the test before bathing, samples 1-4 of the present invention all possess excellent sun protection performance, and their SPF values ​​all exceed 50. By the comparison between samples 1-3, the viscosity of vinyl polydimethylsiloxane has a certain impact on the final SPF value. Selecting a relatively low viscosity (10000cSt) or higher (180000cSt) is relatively unfavorable for the film formation of the sunscreen. Selecting a moderate viscosity (60000cSt) can maintain good spreadability and moldability, and the final SPF value is relatively higher. And by comparing samples 3 and 4, the addition of silica does not have a significant impact on the SPF value before bathing.

[0210] For the test after bathing, it was found that samples 1-3 all showed a decline in SPF values ​​to varying degrees. The viscosity of the vinyl polydimethylsiloxane had a certain impact on the final SPF value. Selecting a relatively low viscosity (10000cSt) or a high viscosity (180000cSt) is relatively unfavorable for the film-forming of the sunscreen. Selecting a moderate viscosity (60000cSt) can maintain good spreadability and moldability, and the final SPF value is relatively higher. In addition, the comparison of samples 3 and 4 revealed that the addition of silica can contribute to the increase of the SPF value after bathing. Its SPF value is well maintained at the level before bathing. This shows that the sunscreen effect of the present invention is not significantly affected when it encounters water, and has the advantage of strong water resistance, can withstand the scouring and destruction of rainwater, seawater, dust and some mechanical stresses from the outside world, and then achieves a waterproof and sweat-resistant sunscreen effect.

[0211] Application Example 2:

[0212] Preparation of dosage form A

[0213] According to the above formula and dosage, 35% vinyl dimethicone (viscosity: 65,000 cSt), 25% hydrogenated dimethicone (viscosity: 45 cSt), 5% dimethicone, 3.00% isononyl isononanoate, 2.50% ethylhexyl salicylate, 6.00% ethylhexyl methoxycinnamate, 2.00% bis-ethylhexyloxyphenol methoxyphenyl triazine, 1.50% diethylamine hydroxybenzoyl benzoate, 4% dimethicone PEG-10 / 15 crosspolymer, and 10% silica silylate were thoroughly mixed at a temperature range of 25°C to 60°C to form the oil phase. 0.2% acrylates / C10-30 alkyl acrylate crosspolymer was added to 3% deionized water and dissolved and fully swollen to form the aqueous phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexylene glycol, and continue adding the aqueous phase. Slowly add the aqueous phase to the oil phase at a temperature between 25°C and 60°C, stirring and homogenizing for 5-15 minutes. Continue stirring and slowly cool to room temperature to form a milky white cream. Store sealed and away from light.

[0214] Preparation of dosage form B

[0215] At a temperature between 45°C and 60°C, uniformly mix 15% cyclopentasiloxane, 1% dimethicone crosspolymer, 4% cetyl PEG / PPG-10 / 1 dimethicone, 1% dimethicone PEG-10 / 15 crosspolymer, 4.5% nylon-12, and isopropyl titanium triisostearate to form the oil phase. Dissolve 48.9% deionized water, 5% glycerin, 15% butylene glycol, 0.3% phenoxyethanol, and 0.3% ethylene glycol to form the aqueous phase. Separately, add 5% of the colloidal platinum composition from Example 1 to form the additive phase. Slowly add the aqueous phase to the oil phase at a temperature between 25°C and 60°C, stirring and homogenizing for 5-15 minutes. Then, add the additive phase and continue stirring and homogenizing for 5-15 minutes to form an opaque gel. Seal and store in a dark place.

[0216] Application Example 3:

[0217] Preparation of dosage form A

[0218] According to the above formula and dosage, 5% vinyl dimethicone (viscosity: 80,000 cSt), 3% hydrogenated dimethicone (viscosity: 100 cSt), 5% dimethicone, 3.00% isononyl isononanoate, 2.00% ethylhexyl salicylate, 5.00% ethylhexyl methoxycinnamate, 2.00% bis-ethylhexyloxyphenol methoxyphenyl triazine, 1.50% diethylamine hydroxybenzoyl hexyl benzoate, 2% dimethicone PEG-10 / 15 crosspolymer, and 1% silica dimethyl silylate were thoroughly mixed at a temperature range of 25°C to 60°C to form the oil phase. 0.5% acrylates / C10-30 alkyl acrylate crosspolymer was added to 50% deionized water and dissolved and fully swollen to form the aqueous phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexylene glycol, and continue adding the aqueous phase. Slowly add the aqueous phase to the oil phase at a temperature between 25°C and 60°C, stirring and homogenizing for 5-15 minutes. Continue stirring and slowly cool to room temperature to form a milky white cream. Store sealed and away from light.

[0219] Preparation of dosage form B

[0220] At a temperature between 45°C and 60°C, uniformly mix 15% cyclopentasiloxane, 1% dimethicone crosspolymer, 4% cetyl PEG / PPG-10 / 1 dimethicone, 1% dimethicone PEG-10 / 15 crosspolymer, 4.5% nylon-12, and isopropyl titanium triisostearate to form the oil phase. Dissolve 53.8% deionized water, 5% glycerin, 15% butylene glycol, 0.3% phenoxyethanol, and 0.3% ethylene glycol to form the aqueous phase. Separately, add 0.1% of the colloidal platinum composition from Example 1 to form the additive phase. Slowly add the aqueous phase to the oil phase at a temperature between 25°C and 60°C, stirring and homogenizing for 5-15 minutes. Then, add the additive phase and continue stirring and homogenizing for 5-15 minutes to form an opaque gel. Seal and store in a dark place.

[0221] Application Example 4:

[0222] Preparation of dosage form A

[0223] According to the above formula and dosage, 20% vinyl dimethicone (viscosity: 80,000 cSt), 10% hydrogenated dimethicone (viscosity: 15 cSt), 5% dimethicone, 3.00% isononyl isononanoate, 2.50% ethylhexyl salicylate, 5.00% ethylhexyl methoxycinnamate, 2.00% bis-ethylhexyloxyphenol methoxyphenyl triazine, 1.50% diethylamine hydroxybenzoyl hexyl benzoate, 4% dimethicone PEG-10 / 15 crosspolymer, and 5% dimethicone silica silylate were thoroughly mixed at a temperature range of 25°C to 60°C to form the oil phase. 0.5% acrylates / C10-30 alkyl acrylate crosspolymer was added to 30% deionized water and dissolved and fully swollen to form the aqueous phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexylene glycol, and continue adding the aqueous phase. Slowly add the aqueous phase to the oil phase at a temperature between 25°C and 60°C, stirring and homogenizing for 5-15 minutes. Continue stirring and slowly cool to room temperature to form a milky white cream. Store sealed and away from light.

[0224] Preparation of dosage form B

[0225] At a temperature between 45°C and 60°C, uniformly mix 15% cyclopentasiloxane, 1% dimethicone crosspolymer, 4% cetyl PEG / PPG-10 / 1 dimethicone, 1% dimethicone PEG-10 / 15 crosspolymer, and 3% silicone resin particles to form the oil phase. Fully dissolve 53.4% ​​deionized water, 5% glycerin, 15% butylene glycol, 0.3% phenoxyethanol, and 0.3% ethylene glycol to form the aqueous phase. Separately add 2% of the colloidal platinum composition from Example 1 to form the additive phase. Slowly add the aqueous phase to the oil phase at a temperature between 25°C and 60°C, stirring and homogenizing for 5-15 minutes. Then, add the additive phase and continue stirring and homogenizing for 5-15 minutes to form an opaque gel. Seal and store in a dark place.

[0226] Application Example 5:

[0227] Preparation of dosage form A

[0228] According to the above formulation, 12% vinyl dimethicone (viscosity: 65,000 cSt), 8% hydrogenated dimethicone (viscosity: 45 cSt), 5% dimethicone, 3.00% isononyl isononanoate, 2.50% ethylhexyl salicylate, 5.00% ethylhexyl methoxycinnamate, 2.00% bis-ethylhexyloxyphenol methoxyphenyl triazine, 1.50% diethylamine hydroxybenzoyl hexyl benzoate, 4% dimethicone PEG-10 / 15 crosspolymer, and 5% dimethicone silica silylate were thoroughly mixed at a temperature range of 25°C to 60°C to form the oil phase. 0.5% acrylates / C10-30 alkyl acrylate crosspolymer was added to 30% deionized water and dissolved and fully swollen to form the aqueous phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexylene glycol, and continue adding the aqueous phase. Slowly add the aqueous phase to the oil phase at a temperature between 25°C and 60°C, stirring and homogenizing for 5-15 minutes. Continue stirring and slowly cool to room temperature to form a milky white cream. Store sealed and away from light.

[0229] Preparation of dosage form B

[0230] At a temperature between 45°C and 60°C, uniformly mix 15% cyclopentasiloxane, 1% dimethicone crosspolymer, 4% cetyl PEG / PPG-10 / 1 dimethicone, 1% dimethicone PEG-10 / 15 crosspolymer, 10% nylon-12, and isopropyl titanium triisostearate to form the oil phase. Fully dissolve 47.4% deionized water, 5% glycerin, 15% butylene glycol, 0.3% phenoxyethanol, and 0.3% ethylene glycol to form the aqueous phase. Separately add 1% of the colloidal platinum composition of Example 5 to form the additive phase. Slowly add the aqueous phase to the oil phase at a temperature between 25°C and 60°C, stirring and homogenizing for 5-15 minutes. Then, add the additive phase and continue stirring and homogenizing for 5-15 minutes to form an opaque gel. Seal and store in a dark place.

[0231] Application Example 6:

[0232] Preparation of dosage form A

[0233] According to the above formulation, 12% vinyl dimethicone (viscosity: 65,000 cSt), 8% hydrogenated dimethicone (viscosity: 45 cSt), 5% dimethicone, 3.00% isononyl isononanoate, 2.00% ethylhexyl salicylate, 5.00% ethylhexyl methoxycinnamate, 2.00% bis-ethylhexyloxyphenol methoxyphenyl triazine, 1.50% diethylamine hydroxybenzoyl hexyl benzoate, 4% dimethicone PEG-10 / 15 crosspolymer, and 5% dimethicone silica silylate were thoroughly mixed at a temperature range of 25°C to 60°C to form the oil phase. 0.5% acrylates / C10-30 alkyl acrylate crosspolymer was added to 30% deionized water and dissolved and fully swollen to form the aqueous phase. Mix the remaining deionized water, 0.25% tromethamine, 0.4% phenoxyethanol, and 0.5% hexylene glycol, and continue adding the aqueous phase. Slowly add the aqueous phase to the oil phase at a temperature between 25°C and 60°C, stirring and homogenizing for 5-15 minutes. Continue stirring and slowly cool to room temperature to form a milky white cream. Store sealed and away from light.

[0234] Preparation of dosage form B

[0235] At a temperature between 45°C and 60°C, mix 15% cyclopentasiloxane, 1% dimethicone crosspolymer, 4% cetyl PEG / PPG-10 / 1 dimethicone, 1% dimethicone PEG-10 / 15 crosspolymer, 1% nylon-12, and isopropyl titanium triisostearate to form the oil phase. Dissolve 56.4% deionized water, 5% glycerin, 15% butylene glycol, 0.3% phenoxyethanol, and 0.3% ethylene glycol to form the aqueous phase. Add 1% of the colloidal platinum composition of Example 6 separately to form the additive phase. Slowly add the aqueous phase to the oil phase at a temperature between 25°C and 60°C, stirring and homogenizing for 5-15 minutes. Then, add the additive phase and continue stirring and homogenizing for 5-15 minutes to form an opaque gel. Store sealed and protected from light.

[0236] Test Example 3: Sunscreen Effect and Waterproof Performance Measurement (Application Examples 2 to 6)

[0237] The test method and process are exactly the same as those described in Test Example 2. The results of Application Examples 2 to 6 are shown in Table 6.

[0238] Table 6: SPF value before and after bathing

[0239]

[0240] As shown in Table 6, in pre-bathing tests, Application Examples 2-6 of the present invention all exhibited excellent sun protection, with SPF values ​​exceeding 50. After bathing, their SPF values ​​remained well above the pre-bathing level. This demonstrates that the sun protection effect of the present invention is not significantly affected by exposure to water, demonstrating its strong water resistance, capable of withstanding erosion and damage from rain, seawater, dust, and certain mechanical stresses, thereby achieving both waterproof and sweat-resistant sun protection.

Claims

1. A sun protection kit comprising: (i) Dosage Form A, comprising: 10-20% by weight of fat, 0.5-30% by weight of a sunscreen, 3-25% by weight of hydrogenated polydimethylsiloxane having a viscosity of 10 to 130 cSt at 25°C, 5-35% by weight of vinyl polydimethylsiloxane having a viscosity of 55,000 to 95,000 cSt at 25°C, 1-10% by weight of an emulsifier, and A cosmetically acceptable carrier; and (ii) Dosage Form B, comprising: 1-10% by weight of a colloidal platinum composition, 1-10% by weight of light scattering particles, A carrier acceptable in the cosmetic field; in, The colloidal platinum composition comprises: 0.1-10% by weight of a metal platinum salt or chloroplatinic acid, 1-20% by weight of fatty acids having 8-30 carbon atoms, 0.01-5% by weight of an organosilane having 10-60 carbon atoms, A solvent acceptable in the cosmetic field, said solvent being propylene glycol, Wherein, the metal platinum salt is selected from: potassium hexachloroplatinate, sodium chloroplatinate, platinum acetylacetonate or a combination thereof.

2. The set according to claim 1, wherein: The dosage form A further comprises 1-10% by weight of silica.

3. The set according to claim 1, wherein: The emulsifier in Formulation A is dimethicone PEG-10 / 15 crosspolymer.

4. The set according to claim 2, wherein: The silica in the dosage form A is selected from the group consisting of silica silylate, silica dimethyl silylate, silica polydimethylsiloxane silylate, hydrated silica or a combination thereof.

5. The set according to claim 1, wherein: The colloidal platinum composition in Formulation B further comprises polyvinyl pyrrolidone having a K value of 28-34.

6. The kit according to claim 1, wherein: The fatty acid in the colloidal platinum composition in the dosage form B is selected from palmitic acid, oleic acid, stearic acid, lauric acid, behenic acid or a combination thereof.

7. The kit according to claim 1, wherein: The organosilane in the colloidal platinum composition in the formulation B is selected from: trimethoxyoctylsilane, triethoxyoctylsilane or a combination thereof.

8. The set according to claim 1, wherein: The light scattering particles in the formulation B are nylon-12 and isopropyl titanium triisostearate.

9. The set according to claim 1, wherein: The formulation B further comprises the following ingredients: silicone oil, silicone elastomer, emulsifier, polyol or a combination thereof.

10. The set according to any one of claims 1 to 9, which is in the form of a double-dose package or two separate packages.

11. A method for non-therapeutic use of the kit according to any one of claims 1 to 9, comprising applying formulation A evenly to the skin surface until absorbed, and then applying formulation B to the skin surface.

Images